loading
Schlusskurs vom Vortag:
$1.96
Offen:
$2.04
24-Stunden-Volumen:
911.07K
Relative Volume:
1.19
Marktkapitalisierung:
$145.14M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-12.05
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
-9.25%
1M Leistung:
-25.90%
6M Leistung:
-84.41%
1J Leistung:
-85.89%
1-Tages-Spanne:
Value
$1.98
$2.15
1-Wochen-Bereich:
Value
$1.90
$2.4051
52-Wochen-Spanne:
Value
$1.90
$19.05

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name
Firmenname
Perspective Therapeutics Inc
Name
Telefon
509-375-1202
Name
Adresse
350 Hills Street, Suite 106, Richland
Name
Mitarbeiter
91
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
CATX's Discussions on Twitter

Vergleichen Sie CATX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
CATX
Perspective Therapeutics Inc
2.06 145.14M 6.96M -46.51M -37.99M -0.1716
Medical Devices icon
ABT
Abbott Laboratories
131.69 225.32B 41.95B 13.40B 6.35B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
100.75 149.74B 16.75B 1.85B 2.37B 1.25
Medical Devices icon
SYK
Stryker Corp
374.75 142.48B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
88.62 113.49B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
72.08 42.10B 5.72B 4.17B 259.90M 6.97

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet H.C. Wainwright Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-11-25 Herabstufung BofA Securities Buy → Neutral
2024-10-24 Eingeleitet UBS Buy
2024-10-01 Eingeleitet Wedbush Outperform
2024-09-25 Eingeleitet Truist Buy
2024-07-25 Eingeleitet BofA Securities Buy
2024-05-09 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten

pulisher
09:35 AM

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance

09:35 AM
pulisher
Apr 01, 2025

Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Apr 01, 2025

Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Perspective Therapeutics Reports 2024 Earnings and Clinical Progress - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Perspective Therapeutics Inc (CATX) Reports Annual EPS Loss of $1.23, Revenue at $1.5 Million, Surpassing Estimates - GuruFocus.com

Mar 26, 2025
pulisher
Mar 26, 2025

Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026 - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Perspective Therapeutics Secures 2-Year Runway with $227M Cash, Advances Cancer Trials - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

CATX stock touches 52-week low at $2.31 amid market fluctuations - Investing.com

Mar 26, 2025
pulisher
Mar 22, 2025

What is HC Wainwright’s Forecast for CATX FY2025 Earnings? - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Brachytherapy Market Expected to Reach USD 1.5 Billion by 2031 | - openPR

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX) - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Perspective Flat on New Drug Trials - Baystreet.ca

Mar 17, 2025
pulisher
Mar 17, 2025

Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register

Mar 15, 2025
pulisher
Mar 15, 2025

Analysts Issue Forecasts for CATX Q4 Earnings - Defense World

Mar 15, 2025
pulisher
Mar 15, 2025

HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Dyne Therapeutics Inc (DYN): A New Perspective - Stocks Register

Mar 14, 2025
pulisher
Mar 14, 2025

Brookline Capital Management Estimates CATX FY2024 Earnings - The AM Reporter

Mar 14, 2025
pulisher
Mar 13, 2025

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Brokers Set Expectations for CATX FY2024 Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Brookline Capital Management - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Perspective Therapeutics at Barclays Healthcare: Radiopharmaceutical Innovations By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 10, 2025

Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target -March 10, 2025 at 08:33 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Scotiabank - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 07, 2025

Scotiabank starts Perspective Therapeutics with Sector Outperform By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank starts Perspective Therapeutics with Sector Outperform - Investing.com

Mar 07, 2025

Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_devices STE
$227.62
price up icon 0.80%
medical_devices ZBH
$112.47
price up icon 0.09%
medical_devices PHG
$24.92
price down icon 1.17%
$67.12
price down icon 0.77%
$79.03
price down icon 0.72%
medical_devices EW
$72.21
price up icon 0.49%
Kapitalisierung:     |  Volumen (24h):